Tau stable isotope labelling kinetics (SILK) and fluid biomarker response to NIO752 – tau MAPT antisense oligonucleotide: an unblinded interim analysis of a phase 1B trial in Alzheimer's disease (CTAD 2026) - Sep 26, 2026 - Abstract #OC20; Pres time: Nov 18, 2026; 08:45 AM - 09:00 AM; No abstract available
Biomarker • P1 data • Alzheimer's Disease • CNS Disorders • MAPT
|
|
Aram ASLANYAN1; Nicolas BARTHÉLEMY2; Chihiro SATO2; Don ELBERT3; Catherine MUMMERY1; Lisa FRENCH1; Guoqiao WANG2; Nupur GHOSHAL2; Eric MCDADE2; Randall BATEMAN2; Ross PATERSON1
|